top of page

Horizon 2020 - Health

With support from Horizon 2020 you will be able to conduct international research projects in support of EU health policies.

With a successful application of the program, companies will receive:

  • 1-5M EUR for technology and product development

  • IPR - Intellectual Property Rights

  • A network of partners for development

  • Access to new markets

  • Technology and knowledge transfer

The purpose of Horizon 2020 Health  is to increase European competitiveness and create new jobs.

Below are the upcoming deadlines for Horizon 2020 Health. Expect 1-2 months for the proposal writing process.

SC1-PM-15-2017: Personalized coaching for well-being and care of people as they age

Deadline: January 31, 2017

Proposals should develop a proof of concept of radically new solutions for a personalized "virtual coach", building upon intelligent ICT environments, access to relevant physiological and behavioral data, new forms of accessible interaction based on tangible user interaction concepts, open platforms and emotional computing . Usability and ease of user interaction should be essential design elements of the "coach".

SC1-PM-16–2017: In-silico trials for developing and evaluating biomedical products

Deadline: March 14, 2017

Proposals will develop innovative in-silico trials for designing, developing and evaluating drugs, radiation and other biomedical and bioactive products.

SC1-PM-17–2017: Personalized computer models and in-silico systems for well-being

Deadline: March 14, 2017

Proposals should aim at the development of new integrative dynamic computer- models and simulation systems of acceptable validity, with the potential to be reused, build on open service platforms and with application in well-being, health and disease.

SC1-PM-03–2017: Diagnostic characterization of rare diseases

Deadline: April 11, 2017

Today many rare diseases still lack means of molecular diagnosis. The aim of this research should be to apply genomics and / or other –omics and / or other high-throughput approaches for the molecular characterization of rare diseases in view of developing molecular diagnoses for a large number of undiagnosed rare diseases.

Ependysis Business Consultants can prepare you in the submission of the investment file, as well as to help you arrange the partners of the project.  

bottom of page